Abstract
The complement system plays an important role in cardiovascular disease in patients on hemodialysis. Vascular calcification is also one of the major causes of cardiovascular disease. We want to investigate the relationship between complement activation and vascular calcification in dialyzed patients. One hundred eight hemodialysis patients and 65 heathy controls were enrolled prospectively. Plasma C3a, C5a, mannose-binding lectin (MBL), and membrane attack complex (MAC or C5b-9) levels were detected using ELISA. Plasma C3c, fB, fH, C1q, and C4 levels were measured by immunity transmission turbidity. Abdominal aortic calcification (AAC) was measured by abdomen lateral plain radiograph, and the AAC score was calculated. We identified increased level of MBL and decreased level of C3c and complement factor B compared with normal control. However, C1q, complement factor H, and C4 levels remained at a similar level compared with individuals with normal renal function. The C3a and C5a levels increased, without change of MAC. Forty two of 108 HD patients had the AAC score. C3a levels were correlated with AAC score (r = 0.461, p = 0.002). The median C3a concentration was 238.72 (196.96, 323.41) ng/mL. When evaluated as AAC categories (≤ 4, > 5) with ordinal logistic regression, univariate analyses revealed that higher C3a levels were associated with severe AAC, while multivariate analyses adjusted for age, sex, and calcium level showed that higher C3a levels (OR, 6.28 (1.25–31.69); p = 0.03) were associated with severe AAC. The areas under the curve (AUC) for C3a to diagnose severe abdominal aortic calcification were 0.75(0.58–0.92, 0.01). The complement system was activated in patients on hemodialysis. Higher C3a levels are independently associated with severe AAC. Plasma C3a might have a diagnostic value for the severe AAC in HD patients.
Similar content being viewed by others
References
Weiner, D. E., Tighiouart, H., Amin, M. G., Stark, P. C., MacLeod, B., Griffith, J. L., Salem, D. N., Levey, A. S., & Sarnak, M. J. (2004). Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol, 15, 1307–1315.
Ekdahl, K. N., Soveri, I., Hilborn, J., Fellstrom, B., & Nilsson, B. (2017). Cardiovascular disease in haemodialysis: Role of the intravascular innate immune system. Nature Reviews. Nephrology, 13, 285–296.
Bolland, M. J., Wang, T. K., van Pelt, N. C., Horne, A. M., Mason, B. H., Ames, R. W., Grey, A. B., Ruygrok, P. N., Gamble, G. D., & Reid, I. R. (2010). Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. Journal of Bone and Mineral Research, 25, 505–512.
Craddock, P. R., Fehr, J., Brigham, K. L., Kronenberg, R. S., & Jacob, H. S. (1977). Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. The New England Journal of Medicine, 296, 769–774.
Hempel, J. C., Poppelaars, F., Gaya da Costa, M., Franssen, C. F., de Vlaam, T. P., Daha, M. R., Berger, S. P., Seelen, M. A., & Gaillard, C. (2017). A: Distinct in vitro complement activation by various intravenous iron preparations. American Journal of Nephrology, 45, 49–59.
Szebeni, J. (2014). Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals. Molecular Immunology, 61, 163–173.
Chenoweth, D. E., Cheung, A. K., & Henderson, L. W. (1983). Anaphylatoxin formation during hemodialysis: Effects of different dialyzer membranes. Kidney International, 24, 764–769.
Poppelaars, F., Gaya da Costa, M., Berger, S. P., Assa, S., Meter-Arkema, A. H., Daha, M. R., van Son, W. J., Franssen, C. F., & Seelen, M. (2016). A: Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients. Journal of Translational Medicine, 14, 236.
Lines, S. W., Richardson, V. R., Thomas, B., Dunn, E. J., Wright, M. J., & Carter, A. M. (2016). Complement and cardiovascular disease--the missing link in haemodialysis patients. Nephron, 132, 5–14.
Szulc, P. (2016). Abdominal aortic calcification: A reappraisal of epidemiological and pathophysiological data. Bone, 84, 25–37.
Nagaraj, N., Matthews, K. A., Shields, K. J., Barinas-Mitchell, E., Budoff, M. J., & El Khoudary, S. R. (2015). Complement proteins and arterial calcification in middle aged women: Cross-sectional effect of cardiovascular fat. The SWAN Cardiovascular Fat Ancillary Study. Atherosclerosis, 243, 533–539.
Honkanen, E., Kauppila, L., Wikstrom, B., Rensma, P. L., Krzesinski, J. M., Aasarod, K., Verbeke, F., Jensen, P. B., Mattelaer, P., & Volck, B. (2008). Group C s: Abdominal aortic calcification in dialysis patients: Results of the CORD study. Nephrology, Dialysis, Transplantation, 23, 4009–4015.
Kauppila, L. I., Polak, J. F., Cupples, L. A., Hannan, M. T., Kiel, D. P., & Wilson, P. W. (1997). New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: A 25-year follow-up study. Atherosclerosis, 132, 245–250.
Foley, R. N., Parfrey, P. S., & Sarnak, M. J. (1998). Epidemiology of cardiovascular disease in chronic renal disease. Journal of the American Society of Nephrology, 9, S16–S23.
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y., & Yang, C. W. (2013). Chronic kidney disease: Global dimension and perspectives. Lancet, 382, 260–272.
Sun, J., Axelsson, J., Machowska, A., Heimburger, O., Barany, P., Lindholm, B., Lindstrom, K., Stenvinkel, P., & Qureshi, A. R. (2016). Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clinical Journal of the American Society of Nephrology, 11, 1163–1172.
Cohen, S. D., Phillips, T. M., Khetpal, P., & Kimmel, P. L. (2010). Cytokine patterns and survival in haemodialysis patients. Nephrology, Dialysis, Transplantation, 25, 1239–1243.
Galli, F. (2016). Complement and cardiovascular disease - the missing link in haemodialysis patients? Nephron, 134, 103.
Poppelaars, F., Gaya da Costa, M., Faria, B., Berger, S. P., Assa, S., Daha, M. R., Medina Pestana, J. O., van Son, W. J., Franssen, C. F. M., & Seelen, M. A. (2018). Intradialytic complement activation precedes the development of cardiovascular events in hemodialysis patients. Frontiers in Immunology, 9, 2070.
Buraczynska, M., Ksiazek, P., Zukowski, P., Benedyk-Lorens, E., & Orlowska-Kowalik, G. (2009). Complement factor H gene polymorphism and risk of cardiovascular disease in end-stage renal disease patients. Clinical Immunology, 132, 285–290.
Hornum, M., Bay, J. T., Clausen, P., Melchior Hansen, J., Mathiesen, E. R., Feldt-Rasmussen, B., & Garred, P. (2014). High levels of mannose-binding lectin are associated with lower pulse wave velocity in uraemic patients. BMC Nephrology, 15(162).
Satomura, A., Endo, M., Fujita, T., Ohi, H., Ohsawa, I., Fuke, Y., Matsumoto, K., Sudo, S., Matsushita, M., & Fujita, T. (2006). Serum mannose-binding lectin levels in maintenance hemodialysis patients: Impact on all-cause mortality. Nephron. Clinical Practice, 102, c93–c99.
Ketteler, M., Bongartz, P., Westenfeld, R., Wildberger, J. E., Mahnken, A. H., Bohm, R., Metzger, T., Wanner, C., Jahnen-Dechent, W., & Floege, J. (2003). Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet, 361, 827–833.
Stenvinkel, P., Wang, K., Qureshi, A. R., Axelsson, J., Pecoits-Filho, R., Gao, P., Barany, P., Lindholm, B., Jogestrand, T., Heimburger, O., Holmes, C., Schalling, M., & Nordfors, L. (2005). Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney International, 67, 2383–2392.
Honda, H., Qureshi, A. R., Heimburger, O., Barany, P., Wang, K., Pecoits-Filho, R., Stenvinkel, P., & Lindholm, B. (2006). Serum albumin, C-reactive protein, interleukin 6, and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. American Journal of Kidney Diseases, 47, 139–148.
Dunkelberger, J. R., & Song, W. C. (2010). Complement and its role in innate and adaptive immune responses. Cell Research, 20, 34–50.
Kang, Y. S., Do, Y., Lee, H. K., Park, S. H., Cheong, C., Lynch, R. M., Loeffler, J. M., Steinman, R. M., & Park, C. G. (2006). A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. Cell, 125, 47–58.
Matsuoka, K., Park, K. A., Ito, M., Ikeda, K., & Takeshita, S. (2014). Osteoclast-derived complement component 3a stimulates osteoblast differentiation. Journal of Bone and Mineral Research, 29, 1522–1530.
Bastos Goncalves, F., Voute, M. T., Hoeks, S. E., Chonchol, M. B., Boersma, E. E., Stolker, R. J., & Verhagen, H. J. (2012). Calcification of the abdominal aorta as an independent predictor of cardiovascular events: A meta-analysis. Heart, 98, 988–994.
Lee, S. M., Lee, H. W., Son, Y. K., Kim, S. E., & An, W. S. (2017). Abdominal aortic calcification score among several vascular calcification scores of plain radiograph is the most reliable predictor of severe coronary artery calcification in dialysis patients. Renal Failure, 39, 729–735.
Figueiredo, C. P., Rajamannan, N. M., Lopes, J. B., Caparbo, V. F., Takayama, L., Kuroishi, M. E., Oliveira, I. S., Menezes, P. R., Scazufca, M., Bonfa, E., & Pereira, R. M. (2013). Serum phosphate and hip bone mineral density as additional factors for high vascular calcification scores in a community-dwelling: The Sao Paulo Ageing & Health Study (SPAH). Bone, 52, 354–359.
Hutcheson, J. D., Goettsch, C., Bertazzo, S., Maldonado, N., Ruiz, J. L., Goh, W., Yabusaki, K., Faits, T., Bouten, C., Franck, G., Quillard, T., Libby, P., Aikawa, M., Weinbaum, S., & Aikawa, E. (2016). Genesis and growth of extracellular-vesicle-derived microcalcification in atherosclerotic plaques. Nature Materials, 15, 335–343.
Shanahan, C. M. (2007). Inflammation ushers in calcification: A cycle of damage and protection? Circulation, 116, 2782–2785.
Carter, A. M., Prasad, U. K., & Grant, P. J. (2009). Complement C3 and C-reactive protein in male survivors of myocardial infarction. Atherosclerosis, 203, 538–543.
Muscari, A., Bozzoli, C., Gerratana, C., Zaca, F., Rovinetti, C., Zauli, D., La Placa, M., & Puddu, P. (1988). Association of serum IgA and C4 with severe atherosclerosis. Atherosclerosis, 74, 179–186.
Engstrom, G., Hedblad, B., Janzon, L., & Lindgarde, F. (2007). Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: A population-based cohort study. European Journal of Cardiovascular Prevention and Rehabilitation, 14, 392–397.
Kostner, K. M., Fahti, R. B., Case, C., Hobson, P., Tate, J., & Marwick, T. H. (2006). Inflammation, complement activation and endothelial function in stable and unstable coronary artery disease. Clinica Chimica Acta, 365, 129–134.
Hoffmeister, H. M., Ehlers, R., Buttcher, E., Kazmaier, S., Szabo, S., Beyer, M. E., Steinmetz, A., & Seipel, L. (2002). Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris. The American Journal of Cardiology, 89, 909–912.
Speidl, W. S., Exner, M., Amighi, J., Mlekusch, W., Sabeti, S., Kastl, S. P., Zorn, G., Maurer, G., Wagner, O., Huber, K., Minar, E., Wojta, J., & Schillinger, M. (2007). Complement component C5a predicts restenosis after superficial femoral artery balloon angioplasty. Journal of Endovascular Therapy, 14, 62–69.
Speidl, W. S., Katsaros, K. M., Kastl, S. P., Zorn, G., Huber, K., Maurer, G., Wojta, J., & Christ, G. (2010). Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. Atherosclerosis, 208, 285–289.
Persson, L., Boren, J., Robertson, A. K., Wallenius, V., Hansson, G. K., & Pekna, M. (2004). Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E−/− low-density lipoprotein receptor −/− mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1062–1067.
Buono, C., Come, C. E., Witztum, J. L., Maguire, G. F., Connelly, P. W., Carroll, M., & Lichtman, A. H. (2002). Influence of C3 deficiency on atherosclerosis. Circulation, 105, 3025–3031.
Yang, X., Peterson, L., Thieringer, R., Deignan, J. L., Wang, X., Zhu, J., Wang, S., Zhong, H., Stepaniants, S., Beaulaurier, J., Wang, I. M., Rosa, R., Cumiskey, A. M., Luo, J. M., Luo, Q., Shah, K., Xiao, J., Nickle, D., Plump, A., Schadt, E. E., Lusis, A. J., & Lum, P. Y. (2010). Identification and validation of genes affecting aortic lesions in mice. The Journal of Clinical Investigation, 120, 2414–2422.
Patel, S., Thelander, E. M., Hernandez, M., Montenegro, J., Hassing, H., Burton, C., Mundt, S., Hermanowski-Vosatka, A., Wright, S. D., Chao, Y. S., & Detmers, P. A. (2001). ApoE(−/−) mice develop atherosclerosis in the absence of complement component C5. Biochemical and Biophysical Research Communications, 286, 164–170.
Albrecht, E. A., Chinnaiyan, A. M., Varambally, S., Kumar-Sinha, C., Barrette, T. R., Sarma, J. V., & Ward, P. A. (2004). C5a-induced gene expression in human umbilical vein endothelial cells. The American Journal of Pathology, 164, 849–859.
Onuma, O. K., Pencina, K., Qazi, S., Massaro, J. M., D'Agostino, R. B., Sr., Chuang, M. L., Fox, C. S., Hoffmann, U., & O'Donnell, C. J. (2017). Relation of risk factors and abdominal aortic calcium to progression of coronary artery calcium (from the Framingham Heart Study). The American Journal of Cardiology, 119, 1584–1589.
Liu, W. C., Wu, C. C., Hung, Y. M., Liao, M. T., Shyu, J. F., Lin, Y. F., Lu, K. C., & Yeh, K. C. (2016). Pleiotropic effects of vitamin D in chronic kidney disease. Clinica Chimica Acta, 453, 1–12.
Tangpricha, V., & Wasse, H. (2014). Vitamin D therapy in kidney disease: More vitamin D is necessary. American Journal of Kidney Diseases, 64, 667–669.
Hou, Y. C., Liu, W. C., Zheng, C. M., Zheng, J. Q., Yen, T. H., & Lu, K. C. (2017). Role of vitamin D in uremic vascular calcification. BioMed Research International, 2017, 2803579.
Funding
This study was funded by the National Natural Science Foundation of China (81270820).
Author information
Authors and Affiliations
Contributions
Y.Q.W., Y.Q.C., and M.H.Z. prepared the manuscript. Y.Q.C. and Y.Q.W. designed the study and organized the coordination. Y.Q.W., Y.Y.M, K.J.G., and X.Y.C collected the specimens and basic characteristics of all the patients. Y.Q.W. performed the experiments and the data analysis. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of Peking University First Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Associate Editor Craig Stolen oversaw the review of this article
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic Supplementary Material
Supplementary Figure 1
Spearman’s correlation analysis of C3a and AAC score. Spearman’s correlation analysis showed that HD patients’ plasma C3a level were positively correlated with AAC score (r = 0.461, p = 0.002) (PNG 72 kb)
Rights and permissions
About this article
Cite this article
Wang, Y., Miao, Y., Gong, K. et al. Plasma Complement Protein C3a Level Was Associated with Abdominal Aortic Calcification in Patients on Hemodialysis. J. of Cardiovasc. Trans. Res. 12, 496–505 (2019). https://doi.org/10.1007/s12265-019-09885-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12265-019-09885-2